NEW YORK, NY / ACCESSWIRE / June 15, 2017 / The Biotech Industry has continued to outperform the broader markets in 2017. Biotech companies appear to be benefitting from a speedier FDA approval process in 2017. There has already been 21 new Novel Drug Approvals so far in 2017, compared to just 22 new approvals in all of 2016.The iShares NASDAQ Biotechnology Index ETF and the SPDR S&P Biotech ETF have posted year-to-date gains of 11.57 and 22.55 percent, respectively, compared to gains of 8.17 percent and 8.89 percent for the Dow Jones Industrial Average and the S&P 500 Index.

RDI Initiates Coverage on:

BioCryst Pharmaceuticals, Inc.
https://ub.rdinvesting.com/news/?ticker=BCRX

TG Therapeutics Inc.
https://ub.rdinvesting.com/news/?ticker=TGTX

BioCryst Pharmaceuticals' shares spiked 5.84 percent to close at $5.80 a share on Tuesday. The stock traded between $5.46 and $5.86 on volume of 1.34 million shares traded. On June 5th, BioCryst announced that its supplemental New Drug Application (sNDA) for a pediatric indication of RAPIVAB has been accepted for review by the FDA. The company is scheduled to present a corporate summary and update regarding the Company's clinical programs at the JMP Securities 2017 Life Sciences Conference in New York on Wednesday, June 21st. Shares of BioCryst Pharmaceuticals have fallen approximately 8.37 percent year-to-date.

"The acceptance of the pediatric sNDA by the FDA represents another important milestone for BioCryst and our partner, Seqirus," said Jon P. Stonehouse, President & Chief Executive Officer. "We are excited the FDA has granted a priority review with the possibility of making RAPIVAB available to treat pediatric patients in the next flu season."

Access RDI's BioCryst Pharmaceuticals Research Report at:
https://ub.rdinvesting.com/news/?ticker=BCRX

TG Therapeutics' shares jumped 5.16 percent to close at $11.20 a share on Tuesday. The stock traded between $10.55 and $11.80 on volume of 3.26 million shares traded. On June 14th, the company reported follow-up data from its ongoing Phase I/Ib trial of TGR-1202 (umbralisib), the Company's oral, next generation PI3K delta inhibitor, in combination with ibrutinib, a BTK inhibitor, in patients with Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL). Shares of TG Therapeutics have gained approximately 140.86 percent year-to-date.

"We continue to be impressed with the safety, tolerability and activity of the combination of TGR-1202 and ibrutinib. With this all oral combination, we are seeing high response rates, including in those patients with prior PI3K inhibitor or ibrutinib exposure. Additionally, the combination was well tolerated with over 30 patients now treated and for durations upwards of 2.5 years in this independently run, investigator initiated study," commented Michael S. Weiss, TG Therapeutics' Executive Chairman and Chief Executive Officer.

Access RDI's TG Therapeutics Research Report at:
https://ub.rdinvesting.com/news/?ticker=TGTX

Our Actionable Research on BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) and TG Therapeutics Inc. (NASDAQ: TGTX) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com